What a Neurosurgeon Should Know About the Endolymphatic Sac: Part 3 – Ménière Disease

Abstract

Objective To elucidate all the aspects that neurosurgeons should know about the Ménière disease (MD).

Methods Review of guidelines, books, and studies from 1933 to 2021, from basic to translational research, using human and animal endolymphatic sac (ES) tissue or cells, as well as reviews, case reports, and papers about surgical experience. This article is divided into three parts. In this last part, we review the MD.

Results The MD is one of the most common pathologies in the ES. It was first described by Prosper Ménière in 1861 with its clinical triad: dizziness, tinnitus, and hearing loss. A lot of theories relating ES to the MD have been proposed. Some of them postulate that it is caused by a narrowing and shortening in the endolymphatic duct, and others relate it to severe inflammation on the ES. Mostly due to the lack of understanding of this pathology, the diagnosis is mainly clinical, despite histopathology being helpful to confirm the diagnosis. The treatment of the MD can be done in 3 different ways: pharmacological, nonpharmacological, and surgical.

Conclusion The MD is one of the most common pathologies in the inner ear and has been largely studied over the years. The latest diagnosis guidelines must help in the classification and give better basis for diagnosis and treatment, which, despite not being curative yet, has improved over the years. Pharmacological treatment based on the possible etiologies, allied with proper diet and routine exercise, is showing promising results.

 

MissingLinkText

Resumo

Objetivo Elucidar todos os aspectos que neurocirurgiões devem saber sobre a doença de Ménière (DM).

Métodos Revisão das diretrizes, livros e estudos de 1933 até 2021, de pesquisa básica até translacional, usando tecidos ou células do saco endolinfático (SE) humanas e animais, além de revisões, relatos de caso e artigos sobre experiencia cirúrgica. Este artigo é dividido em três partes. Nesta última nós revisamos a DM.

Resultados A DM é uma das patologias mais comuns do SE. Ela foi inicialmente descrita por Prosper Ménière em 1861 com a tríade clínica: tontura, zumbido e diminuição da audição. Muitas teorias têm relacionado o SE com a DM. Algumas delas postulam que esta é causada por uma diminuição e estreitamento do ducto endolinfático e outras a relacionam com uma inflamação grave do SE. Principalmente devido à falta de entendimento sobre a patologia, o diagnóstico é primariamente clínico, apesar da Histopatologia ajudar na confirmação diagnóstica. O tratamento da DM pode ser feito de três diferentes formas: farmacológico, não farmacológico e cirúrgico.

Conclusão A DM é um dos distúrbios mais comuns da orelha interna e tem sido muito estudada nos últimos anos. As diretrizes mais recentes devem ajudar na classificação e fornecer mais bases para o diagnóstico e tratamento, que, apesar de ainda não ser curativo, teve grandes avanços ao longo dos anos. O tratamento farmacológico baseado nas teorias etiológicas, aliado com dieta apropriada e exercícios físicos rotineiros, tem mostrado excelentes resultados.

 

MissingLinkText

Keywords

endolymphatic sac - Ménière disease - neurosurgery

Palavras-chave

saco endolinfático - doença de Ménière - neurocirurgia

Introduction

The endolymphatic sac (ES) is a structure situated in the inner ear, together with the cochlea and the semicircular canals, or vestibular system.[1] The ES may be responsible for homeostatic regulation of the inner ear, endolymphatic fluid volume, immune response, elimination of inner ear cellular debris and floating otoconia, membranous labyrinth pressure, acid/basic transport, and the secretion of substances.[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11]

Despite being only 3 mm long in diameter, the ES does not have a very variable location inside the inner ear.[8] Almost every alteration in this structure can cause a massive problem to the hearing, including its loss. The Ménière disease (MD) is one of the most common pathologies of the ES,[12] and it was first described by Prosper Ménière in 1861, with its clinical triad: dizziness, tinnitus, and hearing deafness, with or without aural fullness. Over the years, a lot has changed regarding the definition of this disease but some aspects, like the etiology, are still in debate.[13]

The MD can be treated surgically. Two of the possible procedures are ES decompression and vestibular neurectomy. Pharmacological and nonpharmacological treatments can also help.[12] [14]

In this review, our aim is to elucidate all the aspects that neurosurgeons should know about MD.

 

MissingLinkText

Methodology

This article is divided into three parts. In the third part we review the MD's basic aspects, clinical diagnosis and treatment. We focused on evidence of guidelines, books, and PubMed (from 1933 to 2021) basic and translational research, using human and animal ES tissue or cells, previous reviews about the subject, case reports, and papers about surgical experience. The terms used individually and combined were: Endolymphatic sac; Ménière disease; Neurosurgery. Literature inclusion criteria were: English and Portuguese language only; individual case studies and long-term follow-up studies were included, and duplicate studies were excluded.

First, we briefly approached the basic aspects of MD and its relation to the ES, followed by a review of the clinical diagnosis and treatment. This study may provide a basis to guide neurosurgeons in the evaluation and treatment of this disease.

 

MissingLinkText

Results

Basic Aspects and Relation to the ES

The MD was first described by Prosper Ménière in 1861 with its clinical triad: dizziness, tinnitus, and hearing deafness, with or without aural fullness.[13] However, although some of these original aspects are still present in guidelines, a lot more has been discovered about this disease.

The MD commonly affects adults from 20 to 50 years[13] and is more likely to occur in women.[15] Both ears are affected with the same frequency. Despite the large number of recent studies about the MD, the epidemiology is still unclear, bearing in mind how difficult it is to make an early diagnosis.[13] Although challenging to measure, Alexander and Harris[15] estimate that the prevalence of MS in the United States is 190 per 100,000 habitants.

Part of the trouble in making an early diagnosis of MD lies in its unclear etiology.[13] Studies have raised many theories on its possible causes, but none of them were confirmed. Some of the theories are related to the ES, such as the possibility of a narrowing and shortening in the endolymphatic duct that could hamper the reabsorption of endolymph in the ES, since a smaller duct would allow less endolymph to pass through the duct. Thus, the retained endolymph would elevate the pressure in the endolymphatic space.[13] Another possibility is a reduction of the ES itself, again hampering the reabsorption properties of the ES since the contact surface is smaller.[13] In agreement with that, an experimental obliteration of the ES caused MD symptoms.[16]

It's also possible that due to the immunological properties of the ES,[2] [5] [6] the occurrence of severe inflammation on the ES contributes to tissue fibrosis, further damaging the structure and its function, and generating MD.[13] Another theory, described by Cahali et al.,[13] is related to the stria vascularis, and claims that patients with MD have a significant decrease in the number of vessels, with its transversal section also being smaller. Thus, the vascular deficiency of the stria vascularis represents a possible etiology, mostly because of its importance for the endocochlear potential and endolymph secretion.[13]

There are other explanations for the etiology of MD that are not related to the ES. Glycemic and insulin disorders have been described as possible causes since 90% of the patients with MD have alterations in the glucose and/or insulin levels. Besides that, diet and exercise can diminish the symptomatology of the patients.[13] Hypothyroidism and estrogen insufficiency are among other possible causes.[13]

With fewer observational studies, some authors defend the hypothesis of food allergies (meat, corn, wheat etc.) and stress causing the MD.[13]

 

MissingLinkText

Clinical Diagnosis

The diagnosis of the MD is mainly clinical. Cochlear and vestibular symptoms with aural fullness, in the absence of neurological symptoms, characterize the disease. The MD attacks typically last from minutes to hours, and 96% of the cases also present neurovegetative symptoms. Bilateral tinnitus and hyperacusis are also very common, and can persist during and after the crises, in some cases becoming chronic. Other symptoms are: unilateral loud noise intolerance and sound frequencies distortion.[13]

Despite diagnosis criteria being mainly clinical, some exams can be done to confirm the suspicion.[13] Magnetic resonance imaging (MRI),[16] pure tone audiometry, glycerol test,[17] otoacoustic transport, standard vestibular test, retrocochlear tests, and glycemic and insulin curves[13] can be very helpful. Nevertheless, none of those exams are pathognomonic.[13]

The histopathological exam is the only one that comes close to confirming the diagnosis. Paparella determined that the most important histopathology finding in the MD is the endolymphatic hydrops in the cochlea and saccule. Also, saccule membrane bulging is a common finding.[18]

Using all this information, in 2015, the Barany Society made a guideline for the diagnosis of MD ([Fig. 1]) and created simple and easily applicable diagnosis criteria.[19]

Fig. 1 Ménière disease classification. Adapted from Lopez-Escamez JA et al.[19]

 

MissingLinkText

Treatment

The MD has 3 different types of treatment: pharmacological, nonpharmacological, and surgical.[13] The pharmacological aim is to do a symptomatologic aid, since none of the drug trials were proven to contribute to the healing process. Some of the choices include: hydrochlorothiazide, which increases the potassium concentration in the endolymph, labyrinth depressors, which have anticholinergics, antiemetics, and sedatives. Corticosteroids and vasodilators can also be used, based on the etiology hypothesis of, respectively, fibrosis due to severe inflammation of the ES or stria vascularis ischemia.[13]

Concerning the nonpharmacological treatment, it's possible to interfere in the patient's quality of life with dietary recommendations and routine exercise. A very similar diet for diabetic patients can be used to treat MD, since the high glucose levels can be an etiological factor. Accordingly, a diet rich in potassium and with lower sodium levels may also help. Alcohol consumption and smoking must stop, as well as caffeine, of which can be consumed a maximum of 250 mg per day.[13]

Regarding surgical treatment, two procedures stand out: ES decompression and vestibular neurectomy.[14] The ES procedure for MD was described for the first time by Portmann[20] and it is still used to treat patients' impairment with refractory MD. Hearing impairment and vertigo are the symptoms that have the largest improvement: 19% and 81%, respectively.[14] The operation starts with a bone incision at the retroauricular sulcus level, followed by mastoid opening to expose the lateral sinus. The bony wall of the lateral sinus is separated from the adjacent dura mater (DM), which is then elevated to until it reaches the adherence with the bone. After the vestibular aqueduct and the wall of the fossa are on the same level, it is possible to open the ES. First, the endolymphatic fossa is exposed and pierced in 2 to 3 mm on the ES wall. Afterwards, the opening of the ES must be done in a very delicate way in the connecting point between the dura mater and the rear wall of the petrosal bone.[20]

In 1933, Dandy[21] made the vestibular neurectomy common, but because of the collateral effects and postoperative complications, the procedure was not widely done. In 1991, 58 years later, Silverstein and Rosenberg[22] modified the previous technique and proposed what they called the “combined retrosigmoid/retrolabyrinthine vestibular nerve section”. This technique demonstrated an 85% cure rate, with a 7% chance of enhancing the vertigo. Regarding the hearing loss, Silverstein and Rosenberg identified that 20% of the patients had a change on their audiometry compared to before the surgery and 4% showed substantial hearing loss.[12]

The “combined retrosigmoid/retrolabyrinthine vestibular nerve section” makes a U-shape incision in the postauricular area. Then, a mastoidectomy is required to expose the posterior fossa and the lateral venous sinus. Following, a dural incision is made to reach the cerebellum. The next step is to open the cerebellopontine angle (CPA) arachnoid over the ninth cranial nerve, with the intention of releasing CPA liquid, and releasing the pressure. With the decompression, the cerebellum disconnects itself from the temporal bone allowing for CPA exposure without damaging the cerebellar retraction. At this point, the facial nerve must be identified to prevent damaging it, and the eighth cranial nerve must be examined. After all precautions are taken, the vestibular nerve separation is performed in a cleavage plane between the cochlear and vestibular fibers. If the identification of the cleavage plane fails, the dura mater is reflected off the temporal bone, and the opening of the internal auditory canal is performed using a diamond burr, to enable the division of the superior vestibular and posterior ampullary nerves. To close, the mastoid air cells are sealed with bone wax and the dura with watertight fashion suture. The bony defect is corrected with adipose tissue to present fistulas.[22]

 

MissingLinkText

 

MissingLinkText

Conclusion

The MD is one of the most common pathologies of the inner ear and has been largely studied over the years. Its diagnosis is mainly clinical, which allows a bigger autonomy for medical professionals, but also demands a lot of experience. The latest guidelines must help in the classification of the disease and offer a better basis for diagnosis and treatment options.

The treatment, despite not being curative yet, has improved a lot recently. The pharmacological treatment based on the possible etiologies, allied with proper diet and exercise, is showing promising results. Surgical treatments, especially ES decompression, are procedures that must be taken into consideration for patients who don't respond well to noninvasive therapeutics, and for those who fill the necessary criteria. Knowing this, we highlight the importance of a well-trained doctor to identify and offer the best treatment possible. This study may provide a basis to acquire these skills.

 

MissingLinkText

 

MissingLinkText

Conflict of Interests

The authors have no conflict of interests to declare.

• References

• 1 Kim SH, Nam GS, Choi JY. Pathophysiologic Findings in the Human Endolymphatic Sac in Endolymphatic Hydrops: Functional and Molecular Evidence. Ann Otol Rhinol Laryngol 2019; 128 (6_suppl): 76S-83S
• 2 Altermatt HJ, Gebbers JO, Müller C, Arnold W, Laissue JA. Human endolymphatic sac: evidence for a role in inner ear immune defence. ORL J Otorhinolaryngol Relat Spec 1990; 52 (03) 143-148
• 3 Arnold W, Altermatt HJ, Arnold R, Gebbers JO, Laissue J. Somatostatin (somatostatinlike) immunoreactive cells in the human inner ear. Arch Otolaryngol Head Neck Surg 1986; 112 (09) 934-937
• 4 Arnold W, Altermatt HJ, Gebbers J-O, Laissue J. Secretory immunoglobulin A in the human endolymphatic sac. An immunohistochemical study. ORL J Otorhinolaryngol Relat Spec 1984; 46 (06) 286-288
• 5 Harris JP. Immunology of the inner ear: evidence of local antibody production. Ann Otol Rhinol Laryngol 1984; 93 (2 Pt 1): 157-162
• 6 Harris JP. Immunology of the inner ear: response of the inner ear to antigen challenge. Otolaryngol Head Neck Surg 1983; 91 (01) 18-32
• 7 Kawauchi H, Ichimiya I, Kaneda N, Mogi G. Distribution of immunocompetent cells in the endolymphatic sac. Ann Otol Rhinol Laryngol Suppl 1992; 157 (01) 39-47
• 8 Lundquist PG. Aspects on endolymphatic sac morphology and function. Arch Otorhinolaryngol 1976; 212 (04) 231-240
• 9 Mori N, Miyashita T, Inamoto R. et al. Ion transport its regulation in the endolymphatic sac: suggestions for clinical aspects of Meniere's disease. Eur Arch Otorhinolaryngol 2017; 274 (04) 1813-1820
• 10 Tomiyama S, Harris JP. The role of the endolymphatic sac in inner ear immunity. Acta Otolaryngol 1987; May-Jun; 103 (5–6): 182-188 . PMID: 21449640
• 11 Tomiyama S, Harris JP. The role of the endolymphatic sac in inner car immunology. Acta Otolaryngol 1987; 103 (01) 182-188
• 12 Sajjadi H, Paparella MM. Meniere's disease. Lancet 2008; Aug 2; 372 (9636) 406-414 . PMID: 18675691
• 13 Cahali S, Cahali MB, Lavinsky L, Cahali RB. Hidropisia Endolinfática. In: de Campos CAH, Costa HOO. editors Tratado de otorrinolaringologia. 1rt ed. São Paulo: Rocca; 2003. [phone]
• 14 Bahmad Jr F. Doença/síndrome de Ménière. In: Piltcher OB, da Costa SS, Maahs GS, Kuhl G, authors. Rotinas em otorrinolaringologia. 1rd ed. Porto Alegre: Artamed; 2015: 108-121
• 15 Alexander TH, Harris JP. Current epidemiology of Meniere's syndrome. Otolaryngol Clin North Am 2010; 43 (05) 965-970
• 16 Kimura RS. Experimental blockage of the endolymphatic sac and duct and its effect on the inner ear of the guinea pig. Ann Otol Rhinol Laryngol 1967; 76: 664-687
• 17 Fukuoka H, Takumi Y, Tsukada K. et al. Comparison of the diagnostic value of 3 T MRI after intratympanic injection of GBCA, electrocochleography, and the glycerol test in patients with Meniere's disease. Acta Otolaryngol 2012; 132 (02) 141-145
• 18 Paparella MM. Pathology of Meniere's disease. Ann Otol Rhinol Laryngol Suppl 1984; 112 (01) 31-35
• 19 Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandalà M, Newman-Toker DE, Strupp M, Suzuki M, Trabalzini F, Bisdorff A. Criterios diagnósticos de enfermedad de Menière. Documento de consenso de la Bárány Society, la Japan Society for Equilibrium Research, la European Academy of Otology and Neurotology (EAONO), la American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) y la Korean Balance Society [Diagnostic criteria for Menière's disease. Consensus document of the Bárány Society, the Japan Society for Equilibrium Research, the European Academy of Otology and Neurotology (EAONO), the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and the Korean Balance Society]. Acta Otorrinolaringol Esp 2016; Jan-Feb; 67 (1) 1-7 . Spanish. Doi: 10.1016/j.otorri.2015.05.005. Epub 2015 Aug 12. PMID: 26277738
• 20 Portmann G. Surgical treatment of vertigo by opening of the saccus endolymphaticus. Arch Otolaryngol 1969; 89 (06) 809-815
• 21 Dandy WE. Ménière's disease: symptoms, objective findings and treatment in forty-two cases. Arch Otolaryngol 1934; 20 (01) 1-30
• 22 Silverstein H, Norrell H, Smouha E, Jones R. Combined retrolab-retrosigmoid vestibular neurectomy. An evolution in approach. Am J Otol 1989; May; 10 (3) 166-169 . PMID: 2787602

Publication History

Received: 08 February 2022

Accepted: 06 April 2022

Article published online:
28 June 2023